Showing posts with label gadolinium. Show all posts
Showing posts with label gadolinium. Show all posts
Friday, September 10, 2010
FDA alert: Gadolinium-based Contrast Agents: Class Labeling Change - Risk of Nephrogenic Systemic Fibrosis
RECOMMENDATION: Healthcare professionals should screen patients prior to administration of a GBCA to identify those with acute kidney injury or chronic, severe, kidney disease. See the Drug Safety Communication for the complete list of recommendations to healthcare professionals and patients.
Subscribe to:
Posts
(
Atom
)
